GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2017年度 >
このアイテムの引用には次の識別子を使用してください:
http://hdl.handle.net/10564/3429
|
タイトル: | Periostin cross‑reacts with the renin‑angiotensin system during liver fibrosis development. |
その他のタイトル: | 肝線維化におけるペリオスチンの役割 : レニン・アンギオテンシン系とクロストーク |
著者: | Takeda, Kosuke Noguchi, Ryuichi![](/dspace/image/metalink/link_ja.gif) Kitade, Mitsuteru Namisaki, Tadashi Moriya, Kei Kawaratani, Hideto Okura, Yasushi Kaji, Kosuke Aihara, Yosuke Douhara, Akitoshi Nishimura, Norihisa Sawada, Yasuhiko Seki, Kenichiro Yoshiji, Hitoshi![](/dspace/image/metalink/link_ja.gif) |
キーワード: | periostin angiotensin II liver fibrosis renin-angiotensin system choline-supplemented amino acid |
発行日: | 2017年11月 |
出版者: | Spandidos Publications |
引用: | Molecular medicine reports Vol.16 No.5 p.5752-5758 (2017 Nov) |
抄録: | Periostin is a 90‑kDa extracellular matrix protein, which is secreted primarily from fibroblasts and is expressed in the lungs, kidneys and heart valves. Angiotensin II (AT‑II) serves pivotal roles in the pathogenesis of several diseases with accompanying fibrosis, including chronic liver diseases. AT‑II induces periostin expression by regulating transforming growth factor‑β1 (TGF‑β1)/Smad signaling during cardiac fibrosis. The aim of the present study was to investigate the interaction between AT‑II and periostin during liver fibrosis development. Fischer 344 rats were fed a choline‑deficient L‑amino‑acid (CDAA)‑defined diet for 12 weeks to simulate the development of steatohepatitis with liver fibrosis. Losartan, an AT‑II type I receptor blocker, was administered to inhibit the effect of AT‑II. The therapeutic effect of losartan on hepatic fibrosis development and on periostin expression was then evaluated. Several in vitro experiments were performed to examine the mechanisms underlying the interaction between AT‑II and periostin in activated hepatic stellate cells (Ac‑HSCs). Treatment with losartan suppressed the development of liver fibrosis induced by the CDAA diet, and reduced hepatic periostin expression. In addition, losartan treatment suppressed hepatic Ac‑HSC expansion and hepatic TGF‑β1 expression. In vitro analysis using LX2 HSC cells indicated that AT‑II can augment TGF‑β1 and collagen type I α1 mRNA expression via periostin expression, suggesting that the interaction between AT‑II and periostin may serve a role in liver fibrosis development. In conclusion, blockade of AT‑II‑induced periostin may suppress the progression of liver fibrosis development. |
内容記述: | 博士(医学)・乙第1413号・平成30年3月15日 Copyright: © Takeda et al. This is an open access article distributed under the terms of Creative Commons Attribution License(CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/. |
URI: | http://hdl.handle.net/10564/3429 |
ISSN: | 17912997 |
DOI: | https://doi.org/10.3892/mmr.2017.7356 |
学位授与番号: | 24601B1413 |
学位授与年月日: | 2018-03-15 |
学位名: | 博士(医学) |
学位授与機関: | 奈良県立医科大学 |
出現コレクション: | 2017年度
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|